Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET.
Year: 2010
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: R. Kurzrock, E. E. Cohen, S. I. Sherman, D. G. Pfister, R. B. Cohen, D. Ball, D. S. Hong, C. S. Ng, R. Salgia, M. J. Ratain
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W1901650671